

Prior Authorization of New Drugs

Newly marketed drugs will require prior-authorization by Idaho Medicaid for a minimum of six months after FDA marketing approval. Initial prior authorization criteria will include the FDA approved indications, dosage and place in therapy. Prior authorization requests should be submitted on the Universal PA form available at our website at www.medicaidpharmacy.idaho.gov.

New drugs that are in the same drug class as previously reviewed preferred drug list (PDL) classes will be reviewed with the annual Pharmacy and Therapeutics Committee review of that particular class. The Pharmacy and Therapeutics Committee will determine if a specific new drug should be reviewed mid-cycle prior to the drug class annual review.